Evidence map›Paper›PMID 41626510›Full record

ArticleACS omega2026

Targeting

Martin Juhás, Ghada Bouz, Luping Pang, Stephen D Weeks, Ondřej Jand́ourek, Klára Konečná, Pavla Paterová, Pavel Bárta, Martina Halířová, Marta Kučerová-Chlupáčová and 2 more

Abstract read
In one paragraph

Article in ACS omega, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Martin JuhásFaculty of Pharmacy in Hradec Králové, Charles University, Ak. Heyrovského 1203, Hradec Králové 500 03, Czech Republic.ORCID https://orcid.org/0000-0002-1890-9082
Ghada BouzFaculty of Pharmacy in Hradec Králové, Charles University, Ak. Heyrovského 1203, Hradec Králové 500 03, Czech Republic.
Luping PangDepartment of Medical Genetics and Cell Biology, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, Henan 450001, China.
Stephen D WeeksMedicinal Chemistry, Rega Institute for Medical Research, KU Leuven, Herestraat 49Box 1041, Leuven 3000, Belgium.ORCID https://orcid.org/0000-0002-1360-0852
Ondřej Jand́ourekFaculty of Pharmacy in Hradec Králové, Charles University, Ak. Heyrovského 1203, Hradec Králové 500 03, Czech Republic.ORCID https://orcid.org/0000-0003-4633-2062
Klára KonečnáFaculty of Pharmacy in Hradec Králové, Charles University, Ak. Heyrovského 1203, Hradec Králové 500 03, Czech Republic.
Pavla PaterováDepartment of Clinical Microbiology, University Hospital Hradec Králové, Sokolská 581, Hradec Králové 500 05, Czech Republic.
Pavel BártaFaculty of Pharmacy in Hradec Králové, Charles University, Ak. Heyrovského 1203, Hradec Králové 500 03, Czech Republic.
Martina HalířováFaculty of Pharmacy in Hradec Králové, Charles University, Ak. Heyrovského 1203, Hradec Králové 500 03, Czech Republic.
Marta Kučerová-ChlupáčováFaculty of Pharmacy in Hradec Králové, Charles University, Ak. Heyrovského 1203, Hradec Králové 500 03, Czech Republic.ORCID https://orcid.org/0000-0002-8656-0740
Martin DoležalFaculty of Pharmacy in Hradec Králové, Charles University, Ak. Heyrovského 1203, Hradec Králové 500 03, Czech Republic.
Jan ZitkoFaculty of Pharmacy in Hradec Králové, Charles University, Ak. Heyrovského 1203, Hradec Králové 500 03, Czech Republic.ORCID https://orcid.org/0000-0003-0104-9925

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tuberculosis (TB) remains a significant global health challenge due to the rapid emergence of drug resistance. Despite substantial progress in anti-TB drug development, effective treatment options are limited. In this study, we report the synthesis and biological evaluation of pyrazinamide (PZA) derivatives with 5-alkyl and 5-alkanamido modifications, designed to enhance antimycobacterial activity by increasing lipophilicity and improving penetration of the lipid-rich mycobacterial cell wall. A positive correlation between the length of the 5-alkyl chain and antimycobacterial activity was observed, with maximal potency achieved with the heptyl substituent (

Identifiers

PMID41626510
PMCPMC12854518

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.